The invention relates generally to an accommodating intraocular lens device and, more particularly, to an accommodating intraocular lens device configured for implantation in a lens capsule of a subject's eye.
A cataract is a clouding of the lens in the eye that affects vision. While most cataracts are related to aging, cataracts may also develop as a result of traumatic eye injury, glaucoma, diabetes, steroid use, and exposure to radiation, to name a few. If left untreated, cataracts progress to eventual vision loss and even complete blindness.
Cataracts are typically treated by surgically removing the clouded lens matrix and implanting a replacement artificial intraocular lens (IOL) in the lens capsule that remains. The first generation of implanted IOL devices comprised monofocal lenses, which provided vision correction at only a single distance. Thus, while monofocal lenses provided distance vision, corrective lenses were still required for reading.
Multifocal lenses for IOL devices were introduced to provide vision correction at more than one distance with the goal of obviating the need for additional corrective lenses required with the monofocal lenses. Multifocal lenses typically have areas of varying refractive power to provide vision at multiple distances (e.g., near, intermediate and far). One significant disadvantage to multi focal lenses is the possibility of visual distortions, particularly in the form of glare and halos around light sources at night.
Accommodating IOL devices have recently been introduced as yet another alternative IOL for use in cataract surgery. Accommodating IOL devices typically feature a monofocal lens that is configured to move forward and backward within the eye in response to the eye's natural mechanism of accommodation, thereby allowing the eye to focus on objects across a broad range of distances. Currently, Crystalens® by Bausch and Lomb is the only FDA-approved accommodating IOL on the market in the United States. This device comprises a relatively flat central lens and a pair hinged haptics protruding from the central lens. The haptics respond to the contraction and relaxation of the eye's ciliary muscles to move the central lens portion forward and backward within the eye to provide varying dioptres of power. The Crystalens® device relies solely on the eye's ciliary muscle function in order to provide accommodation. Moreover, because the profile of the Crystalens® device is substantially smaller than that of the natural lens capsule, implantation of this device is followed by shrinkage of the natural lens capsule about the device. As the natural lens capsule shrinks, the zonules are further stretched away from the ciliary muscles, with the attendant loss of the eye's accommodative range.
Dual-lens IOL devices have been developed with the goal of providing a broader range of accommodation that is closer to the eye's natural range. The dual-lens IOL devices typically feature an anterior and a posterior lens in a spaced relation and rely solely on the ciliary muscles to actuate the anterior and posterior lens closer or farther together to alter the distance between them. The varying distance between the anterior and posterior lens provides the accommodation. Examples of dual-lens IOL devices include U.S. Pat. No. 5,275,623, issued to Sarfarazi on Jan. 4, 1994 and U.S. Pub. No. 2006/0178741 to Zadno-Azizi et al., published on Aug. 10, 2006. Dual-lens IOL devices generally suffer the disadvantage of being more complicated in design and requiring larger incisions in the eye for implantation. While the dual-lens IOL devices may hold the potential for providing a greater range of accommodation, they represent a radical departure from the natural lens structure of the eye.
While accommodating IOL devices hold the promise of more fully restoring the natural range of vision for cataract patients, they still fail to substantially mimic the eye's natural mechanism of accommodation. This is primarily because they rely solely on the eye's ciliary muscles to provide the accommodation and fail to respond to other forces which influence the natural accommodative process.
Preferred embodiments of the accommodating intraocular lens (IOL) devices disclosed herein substantially mimic the eye's natural mechanism of accommodation by responding not only to the contraction/relaxation of the ciliary muscles but also to the influence of the viscous body, which bulges forward and exerts a force anteriorly to change the curvature of the lens capsule. Thus, by providing both bilateral displacement and changes in curvature, the accommodating IOL devices disclosed herein provide broader range of accommodation that approximates that found in the natural eye.
In one embodiment, an accommodating IOL device adapted for implantation in the lens capsule of a subject's eye is described. The accommodating IOL device comprises an anterior portion having a refractive optical element, an elastic posterior portion; and an enclosed cavity defined between the anterior and posterior portions. The enclosed cavity is configured to contain a volume of fluid to space apart the anterior and posterior portions. The posterior portion is configured to contact the posterior portion of the lens bag (prior to shrinkage of the lens capsule following implantation) which in turn contacts the vitreous body at least in the area at and surrounding the optical axis when the IOL device is implanted in the eye and the cavity contains the fluid. The posterior portion actuates in response to an anterior force exerted by the vitreous body, causing the fluid to exert a deforming or displacing force on the refractive optical element.
In accordance with a first aspect of this embodiment, the refractive optical element increases its degree of curvature in response to the anterior force and decreases its degree of curvature in the absence of the anterior force.
In accordance with a second aspect of this embodiment, the refractive optical element is resiliently biased to having a degree of curvature that is substantially equal to the degree of curvature of the anterior portion of the subject's natural lens capsule.
In accordance with a third aspect of this embodiment, the IOL device is biased to a configuration having a width that is substantially equal to the width of the unaccommodated natural lens capsule along the optical axis.
In accordance with a fourth aspect of this embodiment, the IOL device has an equatorial diameter that is substantially equal to the equatorial diameter of the subject's natural lens capsule in the unaccommodated state.
In accordance with a fifth aspect of this embodiment, the anterior portion is dimensioned to engage the zonules when the IOL device is implanted in the subject's eye.
In accordance with a sixth aspect of this embodiment, the IOL device further comprises a haptic system coupled to the anterior portion. The haptic system may be configured to substantially center the refractive optical element in the path of the optical axis when implanted in the subject's eye. Alternatively or additionally, the haptic system is configured to bilaterally displace the refractive optical element along the optical axis in response to the contraction and relaxation of the ciliary muscles when the IOL device is implanted in the subject's eye.
In accordance with a seventh aspect of this embodiment, the volume of fluid contained in the cavity is sufficient to space apart the anterior and posterior portions at a distance d3 along the optical axis that is substantially equal to the width of the subject's natural lens capsule along the optical axis d2 in the unaccommodated state.
In another embodiment, an accommodating IOL device adapted for implantation in the lens capsule of a subject's eye is described. The accommodating IOL device comprises an anterior refractive optical element and a membrane comprising a posterior surface. The membrane is coupled to the anterior optical element and defines an enclosed cavity configured to contain a volume of fluid. The posterior portion is configured to contact the posterior portion of the lens capsule which in turn contacts the vitreous body at least in an area at and surrounding the optical axis when the IOL device is implanted in the eye and the cavity contains the fluid. The fluid deforms the anterior refractive optical element in response to an anterior force exerted on the posterior surface by the vitreous body.
In accordance with a first aspect of this embodiment, the anterior optical element further comprises a self-sealing valve to permit the injection of the fluid.
In accordance with a second aspect of this embodiment, the fluid is viscoelastic.
In accordance with a third aspect of this embodiment, the fluid is an aqueous solution of saline or hyaluronic acid.
In accordance with a fourth aspect of this embodiment, the fluid has substantially the same viscosity as the vitreous humor.
In accordance with a fifth aspect of this embodiment, the fluid has substantially the same refractive index as the aqueous humor or the vitreous humor.
In accordance with a sixth aspect of this embodiment, the membrane is coupled to the anterior refractive optical element about its periphery.
In accordance with a seventh aspect of this embodiment, the anterior refractive optical element is contained within the enclosed cavity of the membrane.
In accordance with a eighth aspect of this embodiment, the posterior portion further comprises a reinforced portion.
In a further embodiment, a method for implanting an accommodating intraocular accommodating lens (IOL) device in a subject's eye is described. The method comprises introducing an IOL device in the lens capsule of the subject's eye through an incision in the subject's eye, wherein the IOL device comprises a refractive optical element coupled to an elastic membrane to define an internal cavity; positioning the IOL device within the lens capsule of the subject's eye to substantially center the refractive optical element along an optical axis; and injecting a volume of fluid into the internal cavity of the IOL device sufficient to cause the elastic membrane to contact the posterior portion of the lens capsule which in turn contacts the vitreous body in at least an area at and surrounding the optical axis.
Other objects, features and advantages of the described preferred embodiments will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.
Preferred and non-limiting embodiments of the invention may be more readily understood by referring to the accompanying drawings in which:
Like numerals refer to like parts throughout the several views of the drawings.
Specific, non-limiting embodiments of the present invention will now be described with reference to the drawings. It should be understood that such embodiments are by way of example only and merely illustrative of but a small number of embodiments within the scope of the present invention. Various changes and modifications obvious to one skilled in the art to which the present invention pertains are deemed to be within the spirit, scope and contemplation of the present invention as further defined in the appended claims.
As shown in
The vitreous chamber 160 is located between the lens 130 and the retina 170 and contains another fluid, known as the vitreous humor. The vitreous humor is much more viscous than the aqueous humor and is a transparent, colorless, gelatinous mass. Although much of the volume of the vitreous humor is water, it also contains cells, salts, sugars, vitrosin (a type of collagen), a network of collagen type II fibers with the glycosaminoglycan hyaluronic acid, and proteins. The vitreous has a viscosity two to four times that of pure water, giving it a gelatinous consistency. It also has a refractive index of 1.336.
Unlike the aqueous humor contained in the anterior and posterior chambers 112, 120 of the eye, which is continuously replenished, the vitreous humor is stagnant. The vitreous often becomes less viscous and may even collapse as part of the aging process. It is believed that the collagen fibers of the vitreous humor are held apart by electrical charges. With aging, these charges tend to reduce, and the fibers may clump together. Similarly, the vitreous humor may liquefy, a condition known as syneresis, allowing cells and other organic clusters to float freely within the vitreous humor. These allow floaters which are perceived in the visual field as spots or fibrous strands.
The lens 130 is a clear, crystalline protein membrane-like structure that is quite elastic, a quality that keeps it under constant tension via the attached zonules 140 and ciliary muscles 150. As a result, the lens 130 naturally tends towards a rounder configuration, a shape it must assume for the eye 100 to focus at a near distance as shown in
As shown in
The eye's natural mechanism of accommodation is reflected by the changes in shape of the lens 130 and thus the extent to which it refracts light.
As demonstrated by
The optical element 210 may be made of plastic, silicone, acrylic, or a combination thereof. In accordance with a preferred embodiment, the optical element 210 is made of poly(methyl methacrylate) (PMMA), which is a transparent thermoplastic, sometimes called acrylic glass. Because the optical element 210 is responsible for providing most, if not substantially all, of the refractive power of the IOC device, the optical element 210 is preferably sufficiently flexible so as to change its curvature in response to the contraction/relaxation of the anterior force that is exerted when the vitreous body bulges in the anterior direction.
In accordance with one embodiment, the optical element 210 is resiliently biased to a shape that approximates the shape of a natural and unaccommodated lens (see
In accordance with another embodiment, the optical element 210 is resiliently biased to a shape that approximates the shape of a natural and accommodated lens (see
In the embodiment shown in
Regardless, in engaging the zonules 140, the IOL device responds to part of the accommodative mechanism of the eye in which the ciliary muscles 150 and the zonules 140 cause a bilateral movement of the optical element 210 along the optical axis to thereby provide part of the accommodating response.
The accommodating IOL device 200 is additionally configured to allow the optical element 210 change its shape in response to the forces exerted upon it by the vitreous body 160. This is achieved by providing a flexible optical element 210 and a fluid-filled flexible membrane 230 that is configured to transmit the anterior force of the vitreous body 160 during accommodation to affect the changes in the shape of the lens capsule 130. Preferably, in order to effectuate the transfer of the anterior movements of the vitreous body 160 upon the lens capsule 130, the membrane 230 contacts a substantial area of the posterior surface 134 of the lens capsule 130 and the membrane is sufficiently flexible and substantially devoid of any rigid material that would prevent it from responding to the anterior movements of the vitreous body 160. Thus, the accommodating IOL device 200 is distinguishable from prior art dual lens IOL devices in maintaining a flexible boundary between the lens capsule 130 and the vitreous body 160. In a particularly preferred embodiment, the membrane 230 is sufficiently thin and deformable so as not to impede the natural flexible boundary between the lens capsule 130 and the vitreous body 160.
Moreover, as explained above, there is a degree of shrinkage experienced by the lens capsule 130 after cataract surgery which depends on the profile and the dimension of the IOL device that is implanted in the lens capsule 130. As many of the prior art devices have a profile and/or dimension that is substantially different from the original lens capsule 130 (e.g., by having a smaller width d along the optical axis A-A or a smaller diameter along the equatorial axis B-B), a degree of shrinkage is expected which, in turn, affects the extent to which the lens capsule 130 is engaged to the vitreous body 160. In one preferred embodiment, the IOL device minimizes the degree to which this shrinkage occurs by significantly engaging the contours of the lens capsule 130, particularly the posterior surface 134 of the lens capsule 130 via the fluid filled cavity 220 defined by the optical element 210 and membrane 230. The membrane 230 is preferably configured to contact a substantial, if not substantially all, of the posterior surface 134 of the lens capsule 130 at implantation and before any significant shrinkage of the lens capsule 130 has occurred.
As explained above with respect to
Because the optical element 210 is responsible for providing most, if not substantially all, of the refractive power of the IOC device, the optical element 210 is preferably sufficiently flexible so as to change its curvature in response to the contraction/relaxation of the anterior force that is exerted when the vitreous body bulges in the anterior direction. In a preferred embodiment, the optical element 210 is resiliently biased to a shape that approximates the shape of a natural and unaccommodated lens (see
The flexible membrane 230 may be constructed from any biocompatible elastomeric material. In a preferred embodiment, the flexible membrane 230 has an external surface that approximates the posterior surface of the lens capsule adjacent the vitreous body. The flexible membrane 230 is preferably configured and shaped to contact a substantial, if not the entire, area of the posterior surface of the lens capsule. In a particularly preferred embodiment, this point of contact is at and around the optical axis of the posterior surface.
The flexible membrane 230 is preferably configured to maximize this transfer of force from the vitreous body to the lens 122. As shown in
In accordance with one preferred embodiment, the flexible membrane 230 may have areas of greater and lesser elasticity so as to maximize the translation of the anterior movements of the vitreous body. For example, as shown in
In accordance with another preferred embodiment, the IOL device 200 may be configured to resiliently assume a shape having a width d3 that is substantially equal to the width the lens capsule 130 accommodated eye (see d2 of
In accordance with a further preferred embodiment, the IOL device 200 comprises a single lens. The incorporation of additional lenses in the IOL device would likely interfere with the ability of the lens to deform (i.e., increase its curvature and provide additional diopters of power) to anterior vitreous movement.
The flexible membrane may preferably be made from a polyvinylidene fluoride (PDVF) material. PDVF is believed to allow for the transmission of lasers energy without, itself, becoming degraded. Optionally, a reinforced portion 234 of the flexible membrane 230 may optionally be provided to resist degradation upon the application of lasers of various wavelengths. In a preferred embodiment, the reinforced section 234 is positioned at an area on the membrane 230 corresponding to the optical axis A-A when the IOL device 200 is implanted in the subject's eye. Normally, after cataract surgery, a few of the residual epithelial cells in the lens capsule may migrate to a posterior surface of the bag resulting in various degrees of fibrosis which, in turn, may lead to undesired posterior capsule opacification (PCO). PCO is undesired, particularly at the optical path, and is typically treated by the application of laser pulses (e.g., YAG laser capsulotomy) to burn away the fibrotic membrane. Thus, a reinforced portion 234 may be provided on the membrane 230 as a protective mechanism against the potentially degradative effects of laser treatment on the membrane 230. In a preferred embodiment, the reinforced portion 234 remains flexible and is sized to correspond to the central area at and surrounding the optical axis A-A.
Once the IOL device is implanted in the lens capsule of the patient, a volume of fluid is injected into the cavity 220 via an injection port 212. In a preferred embodiment, the fluid is an aqueous solution of saline or hyaluronic acid and does not provide a significant, or any, contribution to the refractive power of the IOC device. Thus, the function of the fluid is primarily as a vehicle to transfer force resulting from the movement of the vitreous body 150 onto the optical element 210 to provide the accommodation. In a preferred embodiment, the fluid has a viscosity that is substantially the same as the vitreous humor. In another preferred embodiment, the fluid has a refractive index that is substantially the same as the aqueous humor or the vitreous humor.
The IOL device is distinguishable from prior art teachings in which the lens capsule is with various types of polymers, which are injected in liquid form and set with UV or other methods of polymerization. These at have been met with much difficulty as it is often difficult to control the refractive power provided by the polymerized polymers. Here, the refractive power is provided substantially, if not entirely, by the optical element 210 and the fluid that is contained within the cavity 220 does not contribute significantly, if at all, to providing the refractive power of the IOL device. Moreover, unlike the prior art polymers used to fill the lens capsule, the fluid is a relatively inert or biocompatible material, such as saline, or it alternatively contains a high molecular weight compound, such as hyaluronic acid, which does not readily leak from the IOL device 200.
The precise volume of fluid injected into the cavity 220 may differ based on the subject's anatomy, among other factors. The volume of fluid injected into the cavity 220 is not critical so long as it is sufficient to expand the membrane 230 such that the posterior portion of the membrane 230 substantially contacts the posterior portion of the lens capsule and engages the vitreous body of the subject's eye. As explained above, in one preferred embodiment, a volume of fluid is injected into the cavity 220 so as to provide a width d3 of the IOL device along the optical axis A-A substantially approximating the lens width d2 of the accommodated eye 100. In another preferred embodiment, a volume of fluid is injected into the cavity 220 so as to provide a width d3 of the IOL device along the optical axis AA substantially approximating the width d1 of the unaccommodated eye 100.
A haptic system may be incorporated with the IOL device to position the optical element 210 at the optical axis A-A when implanted in the subject's eye. As it is preferable to center the optical element 210 relative to the optical axis A-A, the haptic system preferably comprises a plurality of haptic members extending radially from the IOL device and engaging the zonules 140 surrounding the lens capsule 130 of the eye.
In another embodiment, the optical element 210 may be contained within a flexible membrane 230 that fully encloses the optical element 210. In accordance with this element, flexible membrane 230 has a bag or balloon-like configuration and the spring haptics 350 may be attached either (1) to the optical element 210 itself and protrude from a sealed opening in the flexible membrane 230 or (2) to the flexible membrane 230. Although
In another embodiment, the optical element 210 may be contained within a flexible membrane 230 that fully encloses the optical element 210. In accordance with this element, the spring haptics 450 may be attached either (1) to the optical element 210 itself and protrude from a sealed opening in the flexible membrane 230 or (2) to the flexible membrane 230. Although
The accommodated IOL device shown in
The invention described and claimed herein is not to be limited in scope by the specific preferred embodiments disclosed herein, as these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
The present application is a continuation of U.S. patent application Ser. No. 13/662,087, filed on Oct. 26, 2012, which is a continuation of International Application No. PCT/US2011/034197, filed Apr. 27, 2011, which in turn claims the benefit of U.S. Provisional Application No. 61/343,386, filed Apr. 27, 2010, the contents of which are incorporated herein by reference in their entireties into the present disclosure.
Number | Name | Date | Kind |
---|---|---|---|
4032502 | Lee et al. | Jun 1977 | A |
4373218 | Schachar | Feb 1983 | A |
4512040 | McClure | Apr 1985 | A |
4585457 | Kalb | Apr 1986 | A |
4676791 | LeMaster et al. | Jun 1987 | A |
4720286 | Bailey et al. | Jan 1988 | A |
4731078 | Stoy et al. | Mar 1988 | A |
4822360 | Deacon | Apr 1989 | A |
4842601 | Smith | Jun 1989 | A |
4882368 | Elias et al. | Nov 1989 | A |
4888012 | Horn et al. | Dec 1989 | A |
4892543 | Turley | Jan 1990 | A |
4932966 | Christie et al. | Jul 1990 | A |
5035710 | Nakada et al. | Jul 1991 | A |
5059668 | Fukuda et al. | Oct 1991 | A |
5074876 | Kelman | Dec 1991 | A |
5091121 | Nakada et al. | Feb 1992 | A |
5152788 | Isaacson et al. | Oct 1992 | A |
5167883 | Takemasa et al. | Dec 1992 | A |
5171773 | Chaffe et al. | Dec 1992 | A |
5227447 | Sato et al. | Jul 1993 | A |
5236970 | Christ et al. | Aug 1993 | A |
5264522 | Mize et al. | Nov 1993 | A |
5275623 | Sarfarazi | Jan 1994 | A |
5278258 | Gerace et al. | Jan 1994 | A |
5312860 | Mize et al. | May 1994 | A |
5326506 | Vanderbilt | Jul 1994 | A |
5336487 | Refojo et al. | Aug 1994 | A |
5443506 | Garabet | Aug 1995 | A |
5447987 | Sato et al. | Sep 1995 | A |
5489302 | Skottun | Feb 1996 | A |
5583178 | Oxman et al. | Dec 1996 | A |
5607472 | Thompson | Mar 1997 | A |
5665794 | Maxson et al. | Sep 1997 | A |
5854310 | Maxson | Dec 1998 | A |
6071439 | Bawa et al. | Jun 2000 | A |
6117171 | Skottun | Sep 2000 | A |
6197057 | Peyman et al. | Mar 2001 | B1 |
6361561 | Huo et al. | Mar 2002 | B1 |
6551354 | Ghazizadeh et al. | Apr 2003 | B1 |
6616691 | Tran | Sep 2003 | B1 |
6695881 | Peng et al. | Feb 2004 | B2 |
6730123 | Klopotek | May 2004 | B1 |
6836374 | Esch et al. | Dec 2004 | B2 |
6855164 | Glazier | Feb 2005 | B2 |
6858040 | Nguyen et al. | Feb 2005 | B2 |
6860601 | Shadduck | Mar 2005 | B2 |
6926736 | Peng et al. | Aug 2005 | B2 |
6930838 | Schachar | Aug 2005 | B2 |
6935743 | Shadduck | Aug 2005 | B2 |
6966649 | Shadduck | Nov 2005 | B2 |
6969403 | Peng et al. | Nov 2005 | B2 |
7041134 | Nguyen et al. | May 2006 | B2 |
7063723 | Ran | Jun 2006 | B2 |
7068439 | Esch et al. | Jun 2006 | B2 |
7122053 | Esch | Oct 2006 | B2 |
7150760 | Zhang | Dec 2006 | B2 |
7217288 | Esch et al. | May 2007 | B2 |
7220279 | Nun | May 2007 | B2 |
7223288 | Zhang et al. | May 2007 | B2 |
7226478 | Ting et al. | Jun 2007 | B2 |
7229475 | Glazier | Jun 2007 | B2 |
7238201 | Portney et al. | Jul 2007 | B2 |
7247168 | Esch et al. | Jul 2007 | B2 |
7261737 | Esch et al. | Aug 2007 | B2 |
7264351 | Shadduck | Sep 2007 | B2 |
7276619 | Kunzler et al. | Oct 2007 | B2 |
7278739 | Shadduck | Oct 2007 | B2 |
7316713 | Zhang | Jan 2008 | B2 |
7416562 | Gross | Aug 2008 | B2 |
7438723 | Esch | Oct 2008 | B2 |
7452377 | Watling et al. | Nov 2008 | B2 |
7453646 | Lo | Nov 2008 | B2 |
7485144 | Esch | Feb 2009 | B2 |
7591849 | Richardson | Sep 2009 | B2 |
7637947 | Smith et al. | Dec 2009 | B2 |
7662179 | Sarfarazi | Feb 2010 | B2 |
7675686 | Lo et al. | Mar 2010 | B2 |
7753953 | Yee | Jul 2010 | B1 |
7776088 | Shadduck | Aug 2010 | B2 |
7780729 | Nguyen et al. | Aug 2010 | B2 |
7815678 | Nun | Oct 2010 | B2 |
7842087 | Nun | Nov 2010 | B2 |
7854764 | Nun | Dec 2010 | B2 |
7857850 | Mentak et al. | Dec 2010 | B2 |
7981155 | Cumming | Jul 2011 | B2 |
7985253 | Cumming | Jul 2011 | B2 |
7986465 | Lo et al. | Jul 2011 | B1 |
7998198 | Angelopoulos et al. | Aug 2011 | B2 |
7998199 | Nun | Aug 2011 | B2 |
8012204 | Weinschenk, III et al. | Sep 2011 | B2 |
8018658 | Lo | Sep 2011 | B2 |
8034106 | Mentak et al. | Oct 2011 | B2 |
8034107 | Stenger | Oct 2011 | B2 |
8038711 | Clarke | Oct 2011 | B2 |
8048155 | Shadduck | Nov 2011 | B2 |
8052752 | Woods et al. | Nov 2011 | B2 |
8062361 | Nguyen et al. | Nov 2011 | B2 |
8070806 | Khoury | Dec 2011 | B2 |
8158712 | Your | Apr 2012 | B2 |
8182531 | Hermans et al. | May 2012 | B2 |
8187325 | Zadno-Azizi et al. | May 2012 | B2 |
8197541 | Schedler | Jun 2012 | B2 |
8216306 | Coroneo | Jul 2012 | B2 |
8246679 | Nguyen et al. | Aug 2012 | B2 |
8254034 | Shields et al. | Aug 2012 | B1 |
8257827 | Shi et al. | Sep 2012 | B1 |
8273123 | Nun | Sep 2012 | B2 |
8303656 | Shadduck | Nov 2012 | B2 |
8314927 | Choi et al. | Nov 2012 | B2 |
8320049 | Huang et al. | Nov 2012 | B2 |
8328869 | Smiley et al. | Dec 2012 | B2 |
8361145 | Scholl et al. | Jan 2013 | B2 |
8377124 | Hong et al. | Feb 2013 | B2 |
8398709 | Nun | Mar 2013 | B2 |
8414646 | De Juan, Jr. et al. | Apr 2013 | B2 |
8425597 | Glick et al. | Apr 2013 | B2 |
8425599 | Shadduck | Apr 2013 | B2 |
8430928 | Liao | Apr 2013 | B2 |
8447086 | Hildebrand et al. | May 2013 | B2 |
8454688 | Esch et al. | Jun 2013 | B2 |
8475529 | Clarke | Jul 2013 | B2 |
8496701 | Hermans et al. | Jul 2013 | B2 |
8500806 | Phillips | Aug 2013 | B1 |
8545556 | Woods et al. | Oct 2013 | B2 |
8579972 | Rombach | Nov 2013 | B2 |
8585758 | Woods | Nov 2013 | B2 |
8608799 | Blake | Dec 2013 | B2 |
8608800 | Portney | Dec 2013 | B2 |
8613766 | Richardson et al. | Dec 2013 | B2 |
8647384 | Lu | Feb 2014 | B2 |
8657878 | Mentak et al. | Feb 2014 | B2 |
8668734 | Hildebrand et al. | Mar 2014 | B2 |
8690942 | Hildebrand et al. | Mar 2014 | B2 |
8715345 | DeBoer et al. | May 2014 | B2 |
8715346 | De Juan, Jr. et al. | May 2014 | B2 |
8734509 | Mentak et al. | May 2014 | B2 |
8771347 | DeBoer et al. | Jul 2014 | B2 |
8814934 | Geraghty et al. | Aug 2014 | B2 |
8834565 | Nun | Sep 2014 | B2 |
8858626 | Noy | Oct 2014 | B2 |
8867141 | Pugh et al. | Oct 2014 | B2 |
8900298 | Anvar et al. | Dec 2014 | B2 |
8900300 | Wortz | Dec 2014 | B1 |
8956408 | Smiley et al. | Feb 2015 | B2 |
8968396 | Matthews et al. | Mar 2015 | B2 |
8968399 | Ghabra | Mar 2015 | B2 |
8992609 | Shadduck | Mar 2015 | B2 |
9005282 | Chang et al. | Apr 2015 | B2 |
9005283 | Nguyen et al. | Apr 2015 | B2 |
9034035 | Betser et al. | May 2015 | B2 |
9044317 | Hildebrand et al. | Jun 2015 | B2 |
9072600 | Tran | Jul 2015 | B2 |
9090033 | Carson et al. | Jul 2015 | B2 |
9095424 | Kahook et al. | Aug 2015 | B2 |
9125736 | Kahook et al. | Sep 2015 | B2 |
9186244 | Silvestrini et al. | Nov 2015 | B2 |
9198752 | Woods | Dec 2015 | B2 |
9277987 | Smiley et al. | Mar 2016 | B2 |
9277988 | Chu | Mar 2016 | B1 |
9289287 | Kahook et al. | Mar 2016 | B2 |
9326846 | Devita Gerardi et al. | May 2016 | B2 |
9333072 | Ichikawa | May 2016 | B2 |
9358103 | Wortz et al. | Jun 2016 | B1 |
9364316 | Kahook et al. | Jun 2016 | B1 |
9387069 | Kahook et al. | Jul 2016 | B2 |
9421088 | Kahook et al. | Aug 2016 | B1 |
9427312 | DeBoer et al. | Aug 2016 | B2 |
9433497 | DeBoer et al. | Sep 2016 | B2 |
9456895 | Shadduck | Oct 2016 | B2 |
9486311 | Argento et al. | Nov 2016 | B2 |
9610155 | Matthews | Apr 2017 | B2 |
9622852 | Simonov et al. | Apr 2017 | B2 |
9629712 | Stenger | Apr 2017 | B2 |
9636213 | Brady | May 2017 | B2 |
9655716 | Cumming | May 2017 | B2 |
9681946 | Kahook et al. | Jun 2017 | B2 |
9693858 | Hildebrand et al. | Jul 2017 | B2 |
9713526 | Rombach | Jul 2017 | B2 |
9713527 | Nishi et al. | Jul 2017 | B2 |
9717589 | Simonov et al. | Aug 2017 | B2 |
9744027 | Jansen | Aug 2017 | B2 |
9744028 | Simonov et al. | Aug 2017 | B2 |
9795473 | Smiley et al. | Oct 2017 | B2 |
9808339 | Dorronsoro Diaz et al. | Nov 2017 | B2 |
9814568 | Ben Nun | Nov 2017 | B2 |
9814570 | Robert et al. | Nov 2017 | B2 |
9820849 | Jansen | Nov 2017 | B2 |
9848980 | McCafferty | Dec 2017 | B2 |
9855137 | Smiley et al. | Jan 2018 | B2 |
9855139 | Matthews et al. | Jan 2018 | B2 |
9861469 | Simonov et al. | Jan 2018 | B2 |
9872762 | Scholl et al. | Jan 2018 | B2 |
9872763 | Smiley et al. | Jan 2018 | B2 |
9877825 | Kahook et al. | Jan 2018 | B2 |
9883940 | Nishi et al. | Feb 2018 | B2 |
9925039 | Sohn et al. | Mar 2018 | B2 |
9925040 | Kahook et al. | Mar 2018 | B2 |
9931202 | Borja et al. | Apr 2018 | B2 |
9987126 | Borja et al. | Jun 2018 | B2 |
10004596 | Brady et al. | Jun 2018 | B2 |
10028824 | Kahook et al. | Jul 2018 | B2 |
10045844 | Smiley et al. | Aug 2018 | B2 |
10080648 | Kahook et al. | Sep 2018 | B2 |
10111745 | Silvestrini et al. | Oct 2018 | B2 |
10159564 | Brady et al. | Dec 2018 | B2 |
10195018 | Salahieh et al. | Feb 2019 | B2 |
10195020 | Matthews | Feb 2019 | B2 |
10526353 | Silvestrini | Jan 2020 | B2 |
20020005344 | Heidlas et al. | Jan 2002 | A1 |
20020055776 | Juan, Jr. et al. | May 2002 | A1 |
20020071856 | Dillingham et al. | Jun 2002 | A1 |
20020120329 | Lang et al. | Aug 2002 | A1 |
20030093149 | Glazier | May 2003 | A1 |
20030105522 | Glazier | Jun 2003 | A1 |
20030109926 | Portney | Jun 2003 | A1 |
20030158295 | Fukuda et al. | Aug 2003 | A1 |
20040082993 | Woods | Apr 2004 | A1 |
20040082994 | Woods et al. | Apr 2004 | A1 |
20040111152 | Kelman | Jun 2004 | A1 |
20040148023 | Shu | Jul 2004 | A1 |
20040162612 | Portney et al. | Aug 2004 | A1 |
20040169816 | Esch | Sep 2004 | A1 |
20040249455 | Tran | Dec 2004 | A1 |
20050021139 | Shadduck | Jan 2005 | A1 |
20050071002 | Glazier | Mar 2005 | A1 |
20050107873 | Zhou | May 2005 | A1 |
20050137703 | Chen | Jun 2005 | A1 |
20050251253 | Gross | Nov 2005 | A1 |
20050251254 | Brady et al. | Nov 2005 | A1 |
20050267575 | Nguyen et al. | Dec 2005 | A1 |
20060041307 | Esch et al. | Feb 2006 | A1 |
20060047339 | Brown | Mar 2006 | A1 |
20060069178 | Rastogi et al. | Mar 2006 | A1 |
20060074487 | Gilg | Apr 2006 | A1 |
20060111776 | Glick et al. | May 2006 | A1 |
20060134173 | Liu et al. | Jun 2006 | A1 |
20060135477 | Haitjema et al. | Jun 2006 | A1 |
20060212116 | Woods | Sep 2006 | A1 |
20060238702 | Glick et al. | Oct 2006 | A1 |
20060241752 | Israel | Oct 2006 | A1 |
20070016293 | Tran | Jan 2007 | A1 |
20070032868 | Woods et al. | Feb 2007 | A1 |
20070050024 | Zhang | Mar 2007 | A1 |
20070050025 | Nguyen et al. | Mar 2007 | A1 |
20070078515 | Brady et al. | Apr 2007 | A1 |
20070088433 | Esch et al. | Apr 2007 | A1 |
20070100445 | Shadduck | May 2007 | A1 |
20070106377 | Smith et al. | May 2007 | A1 |
20070118216 | Pynson | May 2007 | A1 |
20070129798 | Chawdhary | Jun 2007 | A1 |
20070129799 | Schedler | Jun 2007 | A1 |
20070129800 | Cumming | Jun 2007 | A1 |
20070129801 | Cumming | Jun 2007 | A1 |
20070132949 | Phelan | Jun 2007 | A1 |
20070213817 | Esch et al. | Sep 2007 | A1 |
20070260308 | Tran | Nov 2007 | A1 |
20070260310 | Richardson | Nov 2007 | A1 |
20080015689 | Esch et al. | Jan 2008 | A1 |
20080033547 | Chang et al. | Feb 2008 | A1 |
20080046074 | Smith et al. | Feb 2008 | A1 |
20080046075 | Esch et al. | Feb 2008 | A1 |
20080046077 | Cumming | Feb 2008 | A1 |
20080051886 | Lin | Feb 2008 | A1 |
20080154364 | Richardson et al. | Jun 2008 | A1 |
20080200982 | Your | Aug 2008 | A1 |
20080269887 | Cumming | Oct 2008 | A1 |
20080300680 | Nun | Dec 2008 | A1 |
20080306587 | Your | Dec 2008 | A1 |
20080306588 | Smiley et al. | Dec 2008 | A1 |
20080306589 | Donitzky et al. | Dec 2008 | A1 |
20090005865 | Smiley et al. | Jan 2009 | A1 |
20090027661 | Choi et al. | Jan 2009 | A1 |
20090043384 | Niwa et al. | Feb 2009 | A1 |
20090116118 | Frazier et al. | May 2009 | A1 |
20090125106 | Weinschenk, III et al. | May 2009 | A1 |
20090149952 | Shadduck | Jun 2009 | A1 |
20090198326 | Zhou et al. | Aug 2009 | A1 |
20090204209 | Tran | Aug 2009 | A1 |
20090204210 | Pynson | Aug 2009 | A1 |
20090264998 | Mentak | Oct 2009 | A1 |
20090292355 | Boyd et al. | Nov 2009 | A1 |
20090319040 | Khoury | Dec 2009 | A1 |
20100004742 | Cumming | Jan 2010 | A1 |
20100055449 | Ota | Mar 2010 | A1 |
20100057095 | Khuray et al. | Mar 2010 | A1 |
20100094412 | Wensrich | Apr 2010 | A1 |
20100094413 | Rombach et al. | Apr 2010 | A1 |
20100131058 | Shadduck | May 2010 | A1 |
20100131059 | Callahan et al. | May 2010 | A1 |
20100179653 | Argento et al. | Jul 2010 | A1 |
20100204787 | Noy | Aug 2010 | A1 |
20100211169 | Stanley et al. | Aug 2010 | A1 |
20100228344 | Shadduck | Sep 2010 | A1 |
20100288346 | Esch | Sep 2010 | A1 |
20100324672 | Esch et al. | Dec 2010 | A1 |
20100324674 | Brown | Dec 2010 | A1 |
20110029074 | Reisin et al. | Feb 2011 | A1 |
20110071628 | Gross et al. | Mar 2011 | A1 |
20110118834 | Lo et al. | May 2011 | A1 |
20110118836 | Jain | May 2011 | A1 |
20110208301 | Anvar et al. | Aug 2011 | A1 |
20110224788 | Webb | Sep 2011 | A1 |
20110282442 | Scholl et al. | Nov 2011 | A1 |
20110288638 | Smiley et al. | Nov 2011 | A1 |
20120016473 | Brady et al. | Jan 2012 | A1 |
20120035724 | Clarke | Feb 2012 | A1 |
20120071972 | Zhao | Mar 2012 | A1 |
20120078364 | Stenger | Mar 2012 | A1 |
20120095125 | Hu et al. | Apr 2012 | A1 |
20120232649 | Cuevas | Sep 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120253458 | Geraghty et al. | Oct 2012 | A1 |
20120253459 | Reich et al. | Oct 2012 | A1 |
20120290084 | Coroneo | Nov 2012 | A1 |
20120296423 | Caffey | Nov 2012 | A1 |
20120296424 | Betser | Nov 2012 | A1 |
20120310341 | Simonov et al. | Dec 2012 | A1 |
20120310343 | Van Noy | Dec 2012 | A1 |
20130006353 | Betser et al. | Jan 2013 | A1 |
20130035760 | Portney | Feb 2013 | A1 |
20130038944 | Chang et al. | Feb 2013 | A1 |
20130060331 | Shadduck | Mar 2013 | A1 |
20130110234 | DeVita et al. | May 2013 | A1 |
20130110235 | Shweigerling | May 2013 | A1 |
20130116781 | Nun | May 2013 | A1 |
20130131794 | Smiley et al. | May 2013 | A1 |
20130190867 | Peyman | Jul 2013 | A1 |
20130231741 | Clarke | Sep 2013 | A1 |
20130250239 | Hildebrand et al. | Sep 2013 | A1 |
20130268070 | Esch et al. | Oct 2013 | A1 |
20130297018 | Brady et al. | Nov 2013 | A1 |
20130317607 | DeBoer et al. | Nov 2013 | A1 |
20130317608 | Hermans et al. | Nov 2013 | A1 |
20140012277 | Matthews et al. | Jan 2014 | A1 |
20140058507 | Reich et al. | Feb 2014 | A1 |
20140085726 | Portney | Mar 2014 | A1 |
20140100654 | Portney et al. | Apr 2014 | A1 |
20140107459 | Lind et al. | Apr 2014 | A1 |
20140111765 | DeBoer et al. | Apr 2014 | A1 |
20140121768 | Simpson | May 2014 | A1 |
20140135917 | Glazier | May 2014 | A1 |
20140135918 | De Juan, Jr. et al. | May 2014 | A1 |
20140142558 | Culbertson et al. | May 2014 | A1 |
20140172092 | Carson et al. | Jun 2014 | A1 |
20140180404 | Tram | Jun 2014 | A1 |
20140180405 | Weinschenk, III et al. | Jun 2014 | A1 |
20140180406 | Simpson | Jun 2014 | A1 |
20140180407 | Sohn et al. | Jun 2014 | A1 |
20140180410 | Gerardi | Jun 2014 | A1 |
20140227437 | DeBoer et al. | Aug 2014 | A1 |
20140228949 | Argento et al. | Aug 2014 | A1 |
20140249625 | Shadduck | Sep 2014 | A1 |
20140257478 | McCafferty | Sep 2014 | A1 |
20140257479 | McCafferty | Sep 2014 | A1 |
20140309734 | Sohn et al. | Oct 2014 | A1 |
20150087743 | Anvar et al. | Mar 2015 | A1 |
20150105760 | Rao et al. | Apr 2015 | A1 |
20150127102 | Wortz | May 2015 | A1 |
20150173892 | Borja et al. | Jun 2015 | A1 |
20150202041 | Shadduck | Jul 2015 | A1 |
20150216652 | Jansen | Aug 2015 | A1 |
20150238310 | Matthews et al. | Aug 2015 | A1 |
20150366656 | Wortz et al. | Dec 2015 | A1 |
20160000558 | Honigsbaum | Jan 2016 | A1 |
20160008126 | Salahieh et al. | Jan 2016 | A1 |
20160051361 | Phillips | Feb 2016 | A1 |
20160058553 | Salahieh et al. | Mar 2016 | A1 |
20160074154 | Woods | Mar 2016 | A1 |
20160184089 | Dudee et al. | Jun 2016 | A1 |
20160184092 | Smiley et al. | Jun 2016 | A1 |
20160208138 | Nishijima et al. | Jul 2016 | A1 |
20160256265 | Borja et al. | Sep 2016 | A1 |
20160262875 | Smith et al. | Sep 2016 | A1 |
20160281019 | Deklippel et al. | Sep 2016 | A1 |
20160287380 | Shi et al. | Oct 2016 | A1 |
20160317287 | Silvestrini et al. | Nov 2016 | A1 |
20170020662 | Shadduck | Jan 2017 | A1 |
20170049561 | Smiley et al. | Feb 2017 | A1 |
20170049562 | Argento et al. | Feb 2017 | A1 |
20170216021 | Brady | Aug 2017 | A1 |
20170247525 | Silverstrini et al. | Aug 2017 | A1 |
20170290658 | Hildebrand et al. | Oct 2017 | A1 |
20170319332 | Kahook et al. | Nov 2017 | A1 |
20170342096 | Silvestrini | Nov 2017 | A1 |
20170348095 | Wortz et al. | Dec 2017 | A1 |
20180014928 | Kahook et al. | Jan 2018 | A1 |
20180028308 | Smiley et al. | Feb 2018 | A1 |
20180110613 | Wortz et al. | Apr 2018 | A1 |
20180125640 | Smiley et al. | May 2018 | A1 |
20180132997 | Smiley et al. | May 2018 | A1 |
20180147051 | Scholl et al. | May 2018 | A1 |
20180153682 | Hajela et al. | Jun 2018 | A1 |
20180161152 | Argento et al. | Jun 2018 | A1 |
20180161153 | Kahook et al. | Jun 2018 | A1 |
20180177589 | Argento et al. | Jun 2018 | A1 |
20180177639 | Rao et al. | Jun 2018 | A1 |
20180256315 | Hildebrand et al. | Sep 2018 | A1 |
20180271642 | Wortz et al. | Sep 2018 | A1 |
20180271645 | Brady et al. | Sep 2018 | A1 |
20180280135 | Otts | Oct 2018 | A1 |
20180296323 | Olcina Portilla | Oct 2018 | A1 |
20180307061 | State et al. | Oct 2018 | A1 |
20180318068 | Otts et al. | Nov 2018 | A1 |
20180344453 | Brady | Dec 2018 | A1 |
20180368971 | Zacher et al. | Dec 2018 | A1 |
20180368973 | Wortz et al. | Dec 2018 | A1 |
20180368974 | Kahook et al. | Dec 2018 | A1 |
20190015198 | Kuiper | Jan 2019 | A1 |
20190021848 | Kahook et al. | Jan 2019 | A1 |
20190069989 | Otts et al. | Mar 2019 | A1 |
20190076239 | Wortz et al. | Mar 2019 | A1 |
20190076243 | Hadba et al. | Mar 2019 | A1 |
20190083235 | Wortz | Mar 2019 | A1 |
20190099263 | Brady et al. | Apr 2019 | A1 |
20190374334 | Brady et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
20 2010 003217 | Aug 2011 | DE |
0356050 | Feb 1990 | EP |
0766540 | Aug 1999 | EP |
1881818 | Jul 2015 | EP |
H09-150002 | Jun 1997 | JP |
2005-511201 | Apr 2005 | JP |
2006-511245 | Apr 2006 | JP |
2006-516002 | Jun 2006 | JP |
2010-514507 | May 2010 | JP |
2013-047290 | Mar 2013 | JP |
WO 9217132 | Oct 1992 | WO |
WO 9929266 | Jun 1999 | WO |
WO 2001034067 | May 2001 | WO |
WO 2004037127 | May 2004 | WO |
WO 2004052242 | Jun 2004 | WO |
WO 2004054471 | Jul 2004 | WO |
WO 2004072689 | Aug 2004 | WO |
WO 2006047383 | May 2006 | WO |
WO 2007005778 | Jan 2007 | WO |
WO 2007047529 | Apr 2007 | WO |
WO 2007047530 | Apr 2007 | WO |
WO 2008024766 | Feb 2008 | WO |
WO 2008031231 | Mar 2008 | WO |
WO 2008077040 | Jun 2008 | WO |
WO 2008082957 | Jul 2008 | WO |
WO 2008103798 | Aug 2008 | WO |
WO 2009015161 | Jan 2009 | WO |
WO 2009015226 | Jan 2009 | WO |
WO 2009015234 | Jan 2009 | WO |
WO 2009015240 | Jan 2009 | WO |
WO 2009064876 | May 2009 | WO |
WO 2010010565 | Jan 2010 | WO |
WO 2010081093 | Jul 2010 | WO |
WO 2011026068 | Mar 2011 | WO |
WO 2011106435 | Sep 2011 | WO |
WO 2011137191 | Nov 2011 | WO |
WO 2012006616 | Jan 2012 | WO |
WO 2012129407 | Sep 2012 | WO |
WO 2013016804 | Feb 2013 | WO |
WO 2013070924 | May 2013 | WO |
WO 2013142323 | Sep 2013 | WO |
WO 2013166068 | Nov 2013 | WO |
WO 2013180254 | Dec 2013 | WO |
WO 2013190130 | Dec 2013 | WO |
WO 2014099630 | Jun 2014 | WO |
WO 2014145562 | Sep 2014 | WO |
WO 2014152017 | Sep 2014 | WO |
WO 2014197170 | Dec 2014 | WO |
WO 2015066502 | May 2015 | WO |
WO 2015066532 | May 2015 | WO |
WO 2015126604 | Aug 2015 | WO |
WO 2016018932 | Feb 2016 | WO |
WO 2016033217 | Mar 2016 | WO |
WO 2016122805 | Aug 2016 | WO |
WO 2016201351 | Dec 2016 | WO |
WO 2017079449 | May 2017 | WO |
WO 2017079733 | May 2017 | WO |
WO 2017087358 | May 2017 | WO |
WO 2017096087 | Jun 2017 | WO |
WO 2017192855 | Nov 2017 | WO |
WO 2018081595 | May 2018 | WO |
WO 2018119408 | Jun 2018 | WO |
WO 2018167099 | Sep 2018 | WO |
WO 2018222579 | Dec 2018 | WO |
WO 2018227014 | Dec 2018 | WO |
WO 2019005859 | Jan 2019 | WO |
WO 2019027845 | Feb 2019 | WO |
Entry |
---|
International Search Report and Written Opinion dated Jul. 14, 2011 for PCT/US2011/034197 in 7 pages. |
Ehrmann, et al., “Biomechanical analysis of the accommodative apparatus in primates”, Clinical and Experimental Optometry, May 2008, vol. 91, Issue 3, pp. 302-312. |
Ehrmann, et al., “Ex Vivo Accommodation Simulator II—Concept and Preliminary Results”, Proceedings of SPIE vol. 5314, Ophthalmic Technologies XIV, Jul. 2004, pp. 48-58. |
Gabel, et al., “Silicone oil with high specific gravity for intraocular use”, British Journal of Ophthalmology, Apr. 1987, vol. 71, 262-267. |
Ghallagher-Wetmore, et al., “Supercritical fluid processing: a new dry technique for photoresist developing”, SPIE's 1995 Symposium on Microlithography, 1995, vol. 2438, 16 pages. |
Lane, et al., “Comparison of the biomechanical behavior of foldable intraocular lenses”, Journal of Cataract Refract Surg, Nov. 2004, vol. 30, pp. 2397-2402. |
Nakamura, et al., “Analysis and Fractionation of Silicone and Fluorosilicone Oils for Intraocular Use”, Investigative Ophthalmology & Visual Science, vol. 31, No. 10, Oct. 1990, 2059-2069. |
National Center for Biotechnology Information. PubChem Substance Database; SID=184590955, https://pubchem.ncbi.nlm.nih.gov/substance/184590955 (accessed Sep. 20, 2017). |
Zhang, et al., “Fluidic adaptive lens with high focal length tunability”, Applied Physics Letters, May 2003, vol. 82, No. 19, pp. 3171-3172. |
Zhang, et al., “Integrated fluidic adaptive zoom lens”, Optics Letters, Dec. 2004, vol. 29, No. 24, pp. 2855-2857. |
Zhao, et al., “Strategies for Supercritical CO2 Fractionation of Polydimethylsiloxane,” Journal of Applied Polymer Science, 1995, vol. 55, 773-778. |
Number | Date | Country | |
---|---|---|---|
20190000612 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
61343386 | Apr 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13662087 | Oct 2012 | US |
Child | 15995671 | US | |
Parent | PCT/US2011/034197 | Apr 2011 | US |
Child | 13662087 | US |